United Kingdom Continuous Glucose Monitoring Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 0.72 Billion |
| Market Size (2027) | USD 0.83 Billion |
| Market Size (2032) | USD 1.73 Billion |
| Growth Rate (2027 - 2032) | 15.91 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
United Kingdom Continuous Glucose Monitoring Market Analysis by Mordor Intelligence
The United Kingdom Continuous Glucose Monitoring Market size was valued at USD 0.72 billion in 2026 and is estimated to grow from USD 0.83 billion in 2027 to reach USD 1.73 billion by 2032, at a CAGR of 15.91% during the forecast period (2027-2032).
According to The British Diabetic Association, the COVID-19 pandemic continued to have a huge impact on society. However, research and data showed that people with diabetes were disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus; that's why preventing or delaying cases of diabetes was more important than ever. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers.
Continuous Glucose Monitoring tests glucose concentration in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed to determine the fluctuation in blood glucose level to take or alter the medication accordingly, especially for insulin users. Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels.
Furthermore, CGM devices allow users to assess past glucose trends through downloaded data while also providing real-time glucose readings on compatible displays. Next-generation products, such as the Abbott FreeStyle Libre 3 and Dexcom G7, have reduced several technical constraints by offering enhanced accuracy, improved connectivity, and greater convenience for users. The Eversense E3 CGM and similar innovations have also improved diabetes monitoring and treatment management for patients and healthcare professionals. Rising awareness of proactive diabetes care and the increasing availability of advanced CGM technologies are expected to drive adoption across the United Kingdom. These developments are likely to create favorable growth opportunities for the market during the forecast period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
United Kingdom Continuous Glucose Monitoring Market Trends and Insights
Growing Diabetes Population in the United Kingdom
The United Kingdom diabetes Population is expected to increase with a CAGR greater than 2% over the forecast period.
In the United Kingdom, the prevalence of diabetes has increased dramatically during the last two decades, driven by the increased prevalence of obesity and lifestyle changes. The country also has the highest obese population, a prominent cause of Type 2 diabetes. According to The British Diabetic Association Diabetes Prevalence, the latest data shows an increase in the number of people living with a diabetes diagnosis in the United Kingdom: an increase of more than 150,000 from the previous year. It is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the United Kingdom. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030, as per IDF 2021 statistics.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of market growth. Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels. The vast range of apps in the diabetes field supports the adoption of lifestyle interventions for the prevention and management of diabetes, the evaluation of blood glucose control quality, and the dosing of insulin. Integration of Continuous Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes additional support needed to improve critical outcomes, thereby enhancing the market prospects in the years to come.
The sensors segment is expected to hold the highest share over the forecast period
Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous Glucose Monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of Continuous Glucose Monitoring devices.
Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, has a much longer lifespan than electrochemical sensors. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
The National Service Framework (NSF) program is improving services by setting national standards to drive service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company interested in diabetes care, from CGM and insulin pumps to apps. Such advantages are likely to drive segment growth over the forecast period.
Competitive Landscape
The United Kingdom Continuous Glucose Monitoring Market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, Medtronic, etc., while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
United Kingdom Continuous Glucose Monitoring Industry Leaders
-
Abbott
-
Medtronics
-
Dexcom
-
GlySens
-
Ascensia
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- October 2022: Abbott announced that a new study published in The New England Journal of Medicine demonstrated that for adults with Type-1 diabetes and suboptimal glycemic control, Abbott's FreeStyle Libre 2 glucose monitoring system provided significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose, which were sustained for the study duration of 24 weeks. The FreeStyle Libre 2 system was also linked to improvements in participant-reported quality of life outcomes, including overall satisfaction and reduced burden associated with glucose monitoring.
- April 2022: Dexcom released G7 in the United Kingdom. The company announced that the G7 is available for people with diabetes aged two years and older in the United Kingdom. Dexcom G7 has the fastest sensor warmup with no finger sticks or scanning required. It is clinically proven to lower A1C and reduce hyper- and hypoglycemia, supported by more peer-reviewed and clinical research.
United Kingdom Continuous Glucose Monitoring Market Report Scope
Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels. A continuous glucose monitor tracks blood sugar levels 24 hours a day. It collects readings automatically every five to 15 minutes and detects trends and patterns to provide a complete picture of diabetes. The United Kingdom Continuous Glucose Monitoring Market is segmented into Component (Sensors and Durables). The report offers the value (USD) and volume (Units) for the above segments.
| Sensors |
| Durables |
| Component | Sensors |
| Durables |
Key Questions Answered in the Report
What is the current market size for the United Kingdom continuous glucose monitoring ?
The United Kingdom continuous glucose monitoring market is valued at USD 0.72 billion in 2026.
Who are the key players in the United Kingdom continuous glucose monitoring market?
Abbott, Medtronics, Dexcom, GlySens and Ascensia are the major companies operating in the United Kingdom continuous glucose monitoring market
What years does this undefined cover?
The report covers the undefined historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the undefined size for years: 2027, 2028, 2029, 2030, 2031, and 2032.